Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on SELLAS Life Sciences Group (NASDAQ:SLS) and maintained a $3 price target for the company's stock.
November 22, 2023 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek reaffirmed an Overweight rating on SELLAS Life Sciences Group with a steady price target of $3.
The reiteration of an Overweight rating and the maintenance of a $3 price target by a reputable analyst like Li Watsek could lead to increased investor confidence in SLS, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100